UNCY - NASDAQ
Unicycive Therapeutics, Inc.
$7.20
+0.56%Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
At a Glance
Live SnapshotUnicycive Therapeutics, Inc. Dividend History
UNCY Dividend Payment History
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
| No dividend payment history available | ||||||
Unicycive Therapeutics, Inc. Payout Ratio Analysis
Dividend Sustainability Analysis
Payout Ratio
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF Payout Ratio
Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.
Dividend Growth
Strong dividend growth demonstrates management confidence and business strength. Excellent signal for long-term dividend investors.
Sustainability
Sustainable dividend with adequate coverage. Some areas for improvement but overall appears safe for dividend investors.
Key Insight
Growth with sustainability: Strong dividend increases coupled with conservative payout ratios suggest robust business momentum and shareholder-friendly management committed to value creation.
Related Guides
Continue your UNCY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.